Trial Profile
A Phase I Study of PTK787/ZK 222584 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Vatalanib (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions
- 30 Apr 2012 Actual patient number is 19 according to ClinicalTrials.gov.
- 30 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jul 2011 Planned end date changed from 1 Sep 2010 to 1 Sep 2011 as reported by ClinicalTrials.gov.